NCT06947850进行中（未招募）4 期
TITLE: Toyos Clinic / A Phase 4 Study to Assess Longer Duration of Treatment With Cenegermin in Moderate to Severe Dry Eye-Associated Neurotrophic Keratitis
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- Toyos Clinic
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- TITLE: Toyos Clinic / A Phase 4 Study to Assess Longer Duration of Treatment with Cenegermin in Moderate to Severe Dry Eye-Associated Neurotrophic Keratitis
研究概览
简要总结
TITLE: Toyos Clinic / A Phase 4 Study to Assess Longer Duration of Treatment with Cenegermin in Moderate to Severe Dry Eye-Associated Neurotrophic Keratitis
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Provision of signed and dated informed consent form and HIPPA authorization.
- •Stated willingness to comply with all study procedures and availability for the duration of the study
- •Male or female, aged 18 to
- •Subjects with moderate to severe ocular pain defined as SANDE questionnaire score of >25 mm at time of screening not due to causes other than dry eye associated with NK in the opinion of the investigator.
- •Have used and/or desired to use an artificial tear substitute for dry eye symptoms in the past 3 months.
- •Have normal lid anatomy.
- •For females of reproductive potential:use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation.
- •For males of reproductive potential:use of condoms or other methods to ensure effective contraception with partner
- •Are postmenopausal (no menstrual cycle for at least one year prior to Visit 1) or have undergone bilateral tubal ligation, hysterectomy, hysterectomy with uni- or bilateral oophorectomy, or bilateral oophorectomy.
- •Patients with stage 1 NK characterized by epithelial irregularity most commonly in the form of punctate keratopathy without epithelial defect or Stage 2 (persistent epithelial defect, PED).
- •PED or corneal ulceration of at least 2 weeks duration refractory to one or more conventional non-surgical treatments for neurotrophic keratitis (e.g., preservative-free artificial tears, gels or ointments; discontinuation of preserved topical drops and medications that can decrease corneal sensitivity; therapeutic contact lenses).
- •Evidence of decreased corneal sensitivity (≤ 4 cm using the Cochet-Bonnet aesthesiometer) within the area of the PED or corneal ulcer and outside of the area of the defect in at least one corneal quadrant.
- •BCDVA of 20/200 or better by Snellen or >/=0.1 decimal units.
排除标准
- •Have a known hypersensitivity or contraindication to the investigational product or their components.
- •Severe systemic allergy.
- •Topical glaucoma medications or oral medications that are not being taken at a stable dose for the past 90 days.
- •Topical dry eye medications within the last month except unpreserved artificial tears which will be allowed throughout the study as needed.
- •Active viral, fungal or bacterial infection or active intraocular inflammation.
- •Subjects must be unwilling to abstain from eyelash growth medications for the duration of the trial.
- •Subjects must not have had penetrating intraocular surgery, refractive surgery or corneal transplantation, eyelid surgery within 12 weeks prior to Visit
- •Febrile illness within one week of screening visit.
- •Treatment with another investigational drug or other investigational intervention withinone month of screening visit.
- •Have serious or severe disease or uncontrolled medical condition that in the judgment of the investigator could confound study assessments or limit compliance.
- •Subjects that are currently pregnant or intend to become pregnant during the course of the study, are breastfeeding, or who are unwilling to use highly effective birth control measures such as hormonal contraceptives, and/or mechanical barrier methods during the course of the trial.
- •Use of contact lenses during trial.
- •Amniotic membranes within two weeks prior to screening.
- •Punctal plugs will be allowed as long as they have remained stable for at least 90 days.
- •No neurostimulation including varencicline, acupuncture or TrueTear or like devices within one month of screening.
研究组 & 干预措施
8 week cenegermin treatment
Active Comparator
All participants receive cenegermin topical ophthalmic drops 20mcg/ml six times daily for a treatment period of either 8 or 16 weeks followed by a follow up period total52 weeks total for each study arm.
干预措施: Cenegermin Ophthalmic Solution [Oxervate] (Drug)
16 week cenegermin
Active Comparator
All participants receive cenegermin topical ophthalmic drops 20mcg/ml six times daily for a treatment period of either 8 or 16 weeks followed by a follow up period total52 weeks total for each study arm.
干预措施: Cenegermin Ophthalmic Solution [Oxervate] (Drug)
结局指标
主要结局
TITLE: Toyos Clinic / A Phase 4 Study to Assess Longer Duration of Treatment with Cenegermin in Moderate to Severe Dry Eye-Associated Neurotrophic Keratitis
时间窗: 8 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Study of Long-term Treatment With Hypertonic Saline in Patients With Cystic FibrosisCystic FibrosisNCT01377792Adelaida Lamas Ferreiro71
已完成
3 期
Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.Chronic Hepatitis CNCT01178996sigma-tau i.f.r. S.p.A.552
已完成
4 期
Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71Hand, Foot and Mouth DiseaseNCT03582761Jiangsu Province Centers for Disease Control and Prevention40,000
Enrolling By Invitation
3 期
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus ErythematosusNCT06475742Viatris Innovation GmbH680
招募中
Unknown
A long term safety follow-up study for subjects who received 3 doses of Pneumococcal Vaccine.CTRI/2024/07/071627Biological E.Limited